Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022843 | 0.95 | HTR2B (0.45) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL5543267 | 0.93 | HTR2B (0.44) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL7634582 | 0.89 | GLA (0.47) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL28248372 | 0.88 | HTR2B (0.54) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL28865565 | 0.88 | HTR2B (0.50) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL24358855 | 0.86 | HTR2B (0.49) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL29732423 | 0.86 | HTR2B (0.49) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL2154019 | 0.84 | GLA (0.53) | HTR2BGLAFFAR1FFAR4MRGPRX4 | |
| SCHEMBL6962952 | 0.83 | DRD2 (0.49) | HTR2BGLAFFAR1FFAR4KCNJ1 | |
| SCHEMBL6960752 | 0.81 | FAAH (0.50) | HTR2BGLAFFAR1FFAR4KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0355583-B1 | Cardiotonics | OTSUKA PHARMA CO LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5266577-A | Method of treating congestive heart failure using carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY LTD. (JP) | 1993-11-30 | — | — | US | disclosed |
| US-5198448-A | Cardiovascular disorders | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1993-03-30 | — | — | US | disclosed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0355583-A2 | Cardiotonics | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR2B 3791/4885GLA 3631/4885FFAR1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.